“Jane brings significant experience and understanding of managing global strategy across the pharmaceutical sector, together with a strong interest in sustainability and diversity,” said Redx.

“Jane has enjoyed a long and successful career in the pharmaceutical sector with Johnson & Johnson.

“During her tenure there she held executive roles in clinical research, international and strategic marketing, product management and operational management. 

“In her last role before retiring in December 2019, Jane was global head of Actelion, where she led the integration of the Swiss biotech business following its acquisition by Johnson & Johnson.

“Prior to that Jane had been company group chair of Janssen EMEA, the group’s research based pharmaceutical arm.

“During her time with Johnson & Johnson, Jane led its Corporate Citizen Trust in EMEA and sponsored its Women’s Leadership Initiative. 

“Jane was also sponsor of Janssen’s Global Pharmaceuticals Sustainability Council.

“Currently, Jane is a non-executive director of the FTSE 100 companies, Johnson Matthey plc, BAE Systems plc, and is a member of the board of directors of TB Alliance, a not-for-profit organisation dedicated to the delivery of affordable tuberculosis drugs.  

“Jane is a past chair of the European Federation of Pharmaceutical Industries and Associations, past Chairwoman of the PhRMA Europe Committee and former member of the Corporate Advisory Board of the UK Government backed ‘Your Life’ campaign, aimed at encouraging more people to study STEM subjects.”

Peter Presland, interim chairman of the board of Redx commented: “We are pleased to welcome Jane as chair of the Redx Board to lead the next stage of the company growth.

“She brings a wealth of pertinent global experience to the company from her long and varied career at Johnson & Johnson, her other board positions and as a fervent champion of sustainability and diversity across business.

“We look forward to drawing on these insights.

“It is a very exciting time for Redx, as we enter into Phase 2 clinical development with RXC004 as a potential treatment for Wnt-ligand driven cancers and continue to progress our Phase 1 study with RXC007 as a potential treatment for fibrotic diseases, including idiopathic pulmonary fibrosis.”

Griffiths said: “I am delighted to be joining Redx at an exciting time as its programmes continue to make progress in the clinic and its research scientists look to further expand the pipeline with differentiated assets.

“I look forward to working closely with the Board and the management team during this next stage of growth.”